One ‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

ConclusionThis meta‐analysis suggests visual improvements at 12 months of 0.5‐mg ranibizumab use in patients with wAMD. A higher gain in VA was observed when pooling results from RCTs compared to those in observational studies.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 9, 2018 Category: Drugs & Pharmacology Authors: Michael Y. Guo, Mahyar Etminan, Jasmine Z. Cheng, Zafar Zafari, David A. L. Maberley Tags: Original Research Article Source Type: research